Emerging Technologies

AR_2016_Pharma-Biotech_210px.pngOur service offerings include process development and manufacturing for cell therapy, viral therapy and antibody drug conjugates. These therapies are seen as the next frontier in medicine.

Lonza Cell Therapy, with decades of experience in cell processing, is an industry leader in process development and manufacturing of cells under current good manufacturing practices (cGMP) for both allogeneic and autologous cell-based therapies. With our broad range of service offerings, combined with our global footprint, we support our clients through the clinical phase to commercial launch.

At our Houston, TX (USA) facility, Lonza Viral Therapy offers services for viral gene and cell therapies through a wide selection of product types, such as adenoviral vectors, adeno-associated virus ​(AAV) vectors and lentiviral vectors. In addition to producing viral vector gene therapies, Houston also performs good manufacturing practice (GMP) processing of virally modified autologous cell therapies. Our full-service offering spans vector design and development, process development and cGMP manufacturing through to product-release testing.

Lonza’s Bioconjugates team has a decade of experience and quality track record in process development and GMP manufacturing of clinical and commercial bioconjugates, including antibody drug conjugates (ADCs). This experience encompasses several bioconjugate constructs and novel payload, linker and conjugation technologies. We have extensive expertise in managing the intricacies of supply chain and safety of these complex products.

Emerging Technologies Overview 2016

Emerging Technologies reported growth in all businesses in 2016 based on strong demand from well-funded biotech and big pharma customers.

The main 2016 highlights for this business included the start of the construction of a new viral therapy facility near Houston, TX (USA). This new facility, which is planned to come online towards the end of 2017, is expected to develop and manufacture both viral gene therapies and virally modified cell therapies.

A further focal point was the announcement of a long-term agreement with bluebird bio, Inc., for dedicated production suites for clinical and commercial supply of viral vectors and virally modified cell therapy products.

For additional information about our services, such as process development, cGMP manufacturing, assay development, analytical and all other related services, click on our websites below: